Y-mAbs Therapeutics, Inc. (YMAB): History, Ownership, Mission, How It Works & Makes Money

Interested in a biopharmaceutical company making strides in cancer treatment? Have you heard of Y-mAbs Therapeutics, Inc. (YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer? Y-mAbs' mission is to become the world leader in developing better and safer antibody-based pediatric oncology products addressing clear unmet medical needs, and with total revenues of $87.7 million for the full year 2024, a 3% increase from 2023, it's worth taking a closer look!

Y-mAbs Therapeutics, Inc. (YMAB) History

Y-mAbs Therapeutics, Inc. Founding Timeline

Year established

Y-mAbs Therapeutics, Inc. was founded in 2015.

Original location

The company is headquartered in New York, NY.

Founding team members

The key people behind the founding of Y-mAbs include:

• Thomas Gad: Founder, Chairman, President, and Head of Business Development
• Claus Moller: Chief Executive Officer

Initial capital/funding

Details on the initial capital and funding for Y-mAbs are not readily available in the provided search results. However, it is common for biotech startups to secure initial funding through venture capital, angel investors, and seed funding rounds.

Y-mAbs Therapeutics, Inc. Evolution Milestones

Y-mAbs Therapeutics, Inc. Transformative Moments

• FDA Approval of DANYELZA® (naxitamab-gqgk) in 2020: This was a pivotal moment as it marked the company's first commercial product, providing a new treatment option for high-risk neuroblastoma and validating its technology platform.
• Initial Public Offering (IPO) in 2017: The IPO provided Y-mAbs with the financial resources necessary to significantly advance its research and development programs.
• Focus on Pediatric Oncology: The strategic decision to focus on developing treatments for pediatric cancers has set Y-mAbs apart and allowed it to address critical unmet needs in this area.

To gain further insights into the company's guiding principles, explore: Mission Statement, Vision, & Core Values of Y-mAbs Therapeutics, Inc. (YMAB).

Y-mAbs Therapeutics, Inc. (YMAB) Ownership Structure

The ownership structure of Y-mAbs Therapeutics, Inc. reflects a mix of institutional, insider, and retail investors, each holding varying percentages of the company's shares.

Y-mAbs Therapeutics, Inc.'s Current Status

Y-mAbs Therapeutics, Inc. is a publicly traded company, listed on the NASDAQ under the ticker symbol YMAB. This status allows the company to raise capital through the issuance of stock to public investors.

Y-mAbs Therapeutics, Inc.'s Ownership Breakdown

The ownership of Y-mAbs Therapeutics, Inc. is distributed among various types of shareholders. The following table provides an overview of the ownership breakdown:

Y-mAbs Therapeutics, Inc.'s Leadership

The leadership team at Y-mAbs Therapeutics, Inc. is responsible for the strategic direction and operational management of the company. Key members of the leadership team include:

• Thomas Gad: Founder, Chairman, and President.
• Claus Moller: Chief Executive Officer.
• Bo Kruse: Chief Financial Officer.

These individuals, along with other members of the executive team, guide the company's efforts in developing and commercializing novel antibody-based cancer therapeutics.

For more in-depth information, consider reading: Exploring Y-mAbs Therapeutics, Inc. (YMAB) Investor Profile: Who’s Buying and Why?

Y-mAbs Therapeutics, Inc. (YMAB) Mission and Values

Y-mAbs Therapeutics, Inc. focuses on developing innovative treatments for cancer, particularly in pediatric oncology, and is dedicated to improving the lives of children with high-unmet medical needs through novel antibody-based therapies.

Y-mAbs Therapeutics, Inc.'s Core Purpose

Official mission statement

Y-mAbs' mission is to 'become the world leader in developing better and safer antibody-based oncology products to improve the survival and quality of life for patients with cancer.'

Vision statement

While a specific, distinct vision statement is not explicitly declared, the vision of Y-mAbs can be inferred from their actions and goals:

• To lead the way in innovative antibody-based cancer treatments, especially for children.
• To significantly improve survival rates and enhance the quality of life for cancer patients.
• To establish itself as a trusted and reliable partner in the oncology community, known for its commitment to patients and innovation.

Company slogan/tagline

Y-mAbs does not have a widely publicized official slogan or tagline. However, considering their focus and mission, a fitting tagline might emphasize their dedication to children and innovation in cancer therapy:

• 'Innovating for a Future Without Childhood Cancer.'
• 'Advancing Hope, One Antibody at a Time.'

To gain more insights into the financial aspects of Y-mAbs Therapeutics, Inc., you might find this resource helpful: Breaking Down Y-mAbs Therapeutics, Inc. (YMAB) Financial Health: Key Insights for Investors

Y-mAbs Therapeutics, Inc. (YMAB) How It Works

Y-mAbs Therapeutics, Inc. is a biopharmaceutical company that focuses on developing and commercializing novel, antibody-based therapeutic products for the treatment of cancer, particularly in pediatric patients.

Y-mAbs Therapeutics, Inc.'s Product/Service Portfolio

Y-mAbs Therapeutics, Inc.'s Operational Framework

Y-mAbs operates through a focused approach encompassing research and development, clinical trials, regulatory approvals, and eventual commercialization of its antibody-based products. Their operations are characterized by:

• Research and Development: Y-mAbs focuses on identifying and developing innovative antibody therapies, particularly those targeting the GD2 and B7-H3 antigens found on cancer cells.
• Clinical Trials: The company conducts clinical trials to evaluate the safety and efficacy of its product candidates. These trials are essential for obtaining regulatory approval from agencies like the FDA.
• Regulatory Affairs: A significant part of Y-mAbs' operations involves navigating the regulatory landscape to secure approvals for their therapies. This includes submitting comprehensive data packages to regulatory agencies.
• Manufacturing: Manufacturing of Y-mAbs' products is a critical operation, often involving partnerships with contract manufacturing organizations (CMOs) to ensure a reliable supply of high-quality therapeutics.
• Commercialization: Upon regulatory approval, Y-mAbs undertakes commercialization activities, including marketing, sales, and distribution of its products. This may involve building their own commercial infrastructure or partnering with other pharmaceutical companies.

More insights about the company can be found here: Mission Statement, Vision, & Core Values of Y-mAbs Therapeutics, Inc. (YMAB).

Y-mAbs Therapeutics, Inc.'s Strategic Advantages

Y-mAbs possesses several strategic advantages that contribute to its competitive positioning within the biopharmaceutical industry:

• Focus on High-Need Pediatric Cancers: By concentrating on difficult-to-treat pediatric cancers like neuroblastoma, Y-mAbs addresses a critical unmet medical need.
• Targeted Immunotherapy Approach: The company's focus on antibody-based therapies allows for a targeted approach to cancer treatment, potentially reducing side effects compared to traditional chemotherapy.
• Proprietary Technology Platforms: Y-mAbs has developed proprietary technology platforms that enable the discovery and development of novel antibody therapeutics.
• Orphan Drug Designations: Many of Y-mAbs' product candidates have received orphan drug designation, which provides certain benefits such as market exclusivity and tax credits.

Y-mAbs Therapeutics, Inc. (YMAB) How It Makes Money

Y-mAbs Therapeutics, Inc. primarily generates revenue through the sales of its approved products, particularly DANYELZA®, and to a lesser extent, through royalty and collaboration revenue related to licensing agreements and partnerships for the development and commercialization of its product candidates.

Y-mAbs Therapeutics, Inc. Revenue Breakdown

Y-mAbs Therapeutics, Inc. Business Economics

The business economics of Y-mAbs Therapeutics are driven by several key factors:

• Pricing Strategy: Y-mAbs prices its primary product, DANYELZA®, to reflect the high value it brings to patients with relapsed or refractory high-risk neuroblastoma. The pricing strategy considers the cost of development, manufacturing, and the clinical benefits offered by the treatment.
• Cost of Goods Sold (COGS): A significant portion of Y-mAbs' expenses is related to the cost of manufacturing DANYELZA®. Managing these costs is crucial for maintaining profitability as sales increase.
• Research and Development (R&D) Expenses: Y-mAbs invests heavily in R&D to expand its pipeline of novel antibody products. These investments are essential for long-term growth but impact short-term profitability.
• Partnerships and Licensing: Strategic collaborations and licensing agreements provide additional revenue streams and help offset development costs. These partnerships also enable Y-mAbs to expand its market reach.

Y-mAbs Therapeutics, Inc. Financial Performance

Y-mAbs' financial performance can be assessed through the following key metrics:

• Revenue Growth: Monitoring the growth in product sales, particularly DANYELZA®, indicates the company's success in penetrating its target market.
• Gross Margin: The gross margin, which is revenue less the cost of goods sold, reflects the efficiency of Y-mAbs' manufacturing and pricing strategies.
• Operating Expenses: Analyzing operating expenses, including R&D and selling, general, and administrative (SG&A) costs, provides insights into the company's investment in future growth and operational efficiency.
• Net Loss: As a biotechnology company, Y-mAbs has historically incurred net losses due to high R&D expenses. However, the trend in net loss and the company's ability to move towards profitability are critical indicators.
• Cash Runway: Assessing the company's cash reserves and burn rate is essential to determine its ability to fund ongoing operations and development programs.

To gain more insights into the financial health of Y-mAbs Therapeutics, Inc., you can explore a detailed analysis here: Breaking Down Y-mAbs Therapeutics, Inc. (YMAB) Financial Health: Key Insights for Investors

Y-mAbs Therapeutics, Inc. (YMAB) Market Position & Future Outlook

Y-mAbs Therapeutics is navigating a competitive biopharmaceutical landscape, focusing on innovative treatments for pediatric cancer. Their future success hinges on clinical trial outcomes, regulatory approvals, and successful commercialization of their product pipeline.

Competitive Landscape

Opportunities & Challenges

Industry Position

Y-mAbs Therapeutics holds a niche position within the biopharmaceutical industry, specifically targeting unmet needs in pediatric oncology. Their standing can be further understood through the following points:

• Specialized Focus: Dedicated to developing and commercializing innovative antibody-based therapies for the treatment of childhood cancers.
• Pipeline Potential: A promising pipeline of product candidates targeting various high-risk, relapsed/refractory pediatric cancers.
• Orphan Drug Designations: Many of their product candidates have received orphan drug designations, which can provide market exclusivity and other benefits.

To gain more insights into the financial aspects of the company, you can explore this resource: Breaking Down Y-mAbs Therapeutics, Inc. (YMAB) Financial Health: Key Insights for Investors